Stella Compagnoni

Dr. Stella Compagnoni

None at the moment
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2022 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
ASAurelio Seidita
Aurelio Seidita
PMPasquale Mansueto
Pasquale Mansueto
SCStella Compagnoni
Stella Compagnoni
DCDaniele Castellucci
Daniele Castellucci
MSMaurizio Soresi
Maurizio Soresi
ACAntonio Carroccio
Antonio Carroccio
Anemia is considered to be the most frequent extra-intestinal manifestation of Celiac Disease (CD). We assessed frequency, severity, morphologic features, and pathogenic factors of anemia in patients of the Sicilian Regional Network of Celiac Disease and attempted to identify putative pre-diet factors influencing anemia persistence. We retrospectively analyzed CD patients admitted to three centers between 2016–2020. 159 patients entered the study (129 females). More than half (54.7%) had mild-moderate, hypochromic and microcytic anemia, associated with below normal total serum iron and ferritin, indicative of iron deficiency anemia (IDA). One year after diagnosis, 134 patients were following ‘strict’ GFD. Hypochromic and microcytic anemia persisted in 46% of subjects who were anemic at diagnosis. Patients with persistent anemia had at diagnosis a higher prevalence of female gender (p = 0.02), lower body mass index (BMI, p = 0.01), higher prevalence of poly/hypermenorrhea (p = 0.02) and atopy (p = 0.04), and lower ferritin levels (p = 0.05) than the whole group of non-anemic ones. IDA is found in more than 50% of CD patients at diagnosis; nevertheless, in a lot of women IDA is not corrected by ‘strict’ GFD. Low BMI and poly/hypermenorrhea at diagnosis characterize this subgroup, suggesting that IDA might be due to iron loss rather than malabsorption, or to their coexistence/overlap.

8 June 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
ACAntonio Carroccio
Antonio Carroccio
MSMaurizio Soresi
Maurizio Soresi
MCMarta Chiavetta
Marta Chiavetta
FBFrancesco La Blasca
Francesco La Blasca
SCStella Compagnoni
Stella Compagnoni
PMPasquale Mansueto
Pasquale Mansueto
Background: Non-Celiac Wheat Sensitivity (NCWS) is characterized by both intestinal and extra-intestinal symptoms. The study aims to investigate the frequency of neuropsychiatric manifestations in NCWS patients and identify their clinical and demographic characteristics. Methods: 278 clinical records of NCWS patients, diagnosed by a double-blind placebo-controlled wheat challenge between 2006 and 2020, were retrospectively revised. Fifty-two patients with Celiac Disease (CD) and 54 patients with Irritable Bowel Syndrome (IBS) served as controls. Results: 87% of the NCWS patients had an IBS-like clinical presentation. The NCWS group showed a longer duration of symptoms, a higher frequency of positive serum anti-nuclear antibodies than CD and IBS patients, and a higher frequency of DQ2/DQ8 haplotypes and duodenal mucosa lymphocytosis than IBS controls. In addition, 50% of NCWS patients showed neuropsychiatric manifestations, while lower percentages were observed in CD (25%) and IBS (28%) controls. Neuropsychiatric symptoms in NCWS were more frequently associated with the male sex, longer duration of symptoms, and IBS-diarrhea-like clinical presentation. Conclusions: Our data suggest that in patients with IBS-like symptoms and neuropsychiatric manifestations of unknown cause, it could be useful to investigate a correlation of these symptoms with wheat ingestion to identify NCWS patients with this ‘atypical’ manifestation.

29 October 2024 in Italian Journal of Medicine
Verified
Journal Article
Open access
PDF file
ASAurelio Seidita
Aurelio Seidita
FMFrancesca Mandreucci
Francesca Mandreucci
MPMirco Pistone
Mirco Pistone
SCSilvia Calderone
Silvia Calderone
AGAlessandra Giuliano
Alessandra Giuliano
SCStella Compagnoni
Stella Compagnoni
The aim of this brief report is to evaluate sodium-glucose cotransporter 2 inhibitors (SGLT2-I) effects on patients with both refractory ascites and type 2 diabetes mellitus (T2D). We consecutively recruited all the diabetic patients with refractory ascites due to decompensated liver cirrhosis admitted between February and May 2023 at the Internal Medicine Unit of the University Hospital of Palermo. Clinical and laboratory data were collected after starting SGLT2-I therapy. SGLT2-I use was associated with a reduction/resolution of ascites and with an improvement in serum albumin and sodium levels and estimated glomerular filtration rate. SGLT2-I might represent a valid therapeutic option in the treatment of patients with refractory ascites and T2D, as already hypothesized by other research groups.

30 April 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
ASAurelio Seidita
Aurelio Seidita
SCStella Compagnoni
Stella Compagnoni
MPMirco Pistone
Mirco Pistone
ACAntonio Carroccio
Antonio Carroccio
Despite the rapid progress that has considerably affected most fields of medicine in recent years, many gray areas still exist in our understanding of allergies/hypersensitivities and intolerances to foods